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Abstract
Background: Proteomic studies of respiratory disorders have the potential to identify protein biomarkers for
diagnosis and disease monitoring. Utilisation of sensitive quantitative proteomic methods creates opportunities to
determine individual patient proteomes. The aim of the current study was to determine if quantitative proteomics
of bronchial biopsies from asthmatics can distinguish relevant biological functions and whether inhaled
glucocorticoid treatment affects these functions.
Methods: Endobronchial biopsies were taken from untreated asthmatic patients (n = 12) and healthy controls (n =
3). Asthmatic patients were randomised to double blind treatment with either placebo or budesonide (800 μg
daily for 3 months) and new biopsies were obtained. Proteins extracted from the biopsies were digested and
analysed using isobaric tags for relative and absolute quantitation combined with a nanoLC-LTQ Orbitrap mass
spectrometer. Spectra obtained were used to identify and quantify proteins. Pathways analysis was performed
using Ingenuity Pathway Analysis to identify significant biological pathways in asthma and determine how the
expression of these pathways was changed by treatment.
Results: More than 1800 proteins were identified and quantified in the bronchial biopsies of subjects. The pathway
analysis revealed acute phase response signalling, cell-to-cell signalling and tissue development associations with
proteins expressed in asthmatics compared to controls. The functions and pathways associated with placebo and
budesonide treatment showed distinct differences, including the decreased association with acute phase proteins
as a result of budesonide treatment compared to placebo.
Conclusions: Proteomic analysis of bronchial biopsy material can be used to identify and quantify proteins using
highly sensitive technologies, without the need for pooling of samples from several patients. Distinct
pathophysiological features of asthma can be identified using this approach and the expression of these features is
changed by inhaled glucocorticoid treatment. Quantitative proteomics may be applied to identify mechanisms of
disease that may assist in the accurate and timely diagnosis of asthma.
Trial registration: ClinicalTrials.gov registration NCT01378039
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Asthma is one of the most common chronic diseases in
the world and poses a vast burden on society with lim-
ited new treatments being developed [1,2]. Understand-
ing asthma has proven to be a challenge, although
immunological tools and genomic studies have started
to dissect mechanisms of asthma using animal models
and cell cultures expressing certain limited characteris-
tics of the disease. However, human asthma is not
totally reflected in these systems, therefore the identifi-
cation of the mechanisms of human disease and their
interactions is needed.
In humans, the investigation of asthma mechanisms is
commonly explored using clinical examinations and
relatively small patient samples. The gene and protein
investigation of asthma pathogenesis has progressed
from local to global studies. Genomic efforts to identify
genes and mechanisms related to asthma pathogenesis
in humans have identified multiple areas of interest, as
reviewed by Rolph et al [3]. While genomic studies pro-
vide a wealth of information, it is their translated pro-
ducts, the proteins, which direct cellular functions. The
global proteome in asthma has yet to be thoroughly
investigated, which may more efficiently identify
mechanisms and markers of asthma.
To date, the proteomic studies of asthma fall into
three broad categories; tissues, fluids and cells, each pos-
ing different analytical challenges. The majority of stu-
dies concerning asthma have been conducted on
bronchoalveolar lavage fluid (BALF) and lung tissue of
mouse models [4-7], which can only represent certain
features of asthma. The few efforts in human asthma
have mainly centred around cell cultures [8], sputum
[9], BALF [10], T lymphocytes [11] and more recently,
exhaled breath condensate [12]. While these samples
present aspects of asthma, they do not totally reflect the
site of disease, the bronchi. These proteomics studies
have generated a list of identified proteins using meth-
ods like SDS-PAGE, 2-DE, LC-MS/MS, SELDI-TOF and
MALDI-TOF [13]. Despite being successively used in
other fields [14-18], the use of quantitative proteomics,
specifically isobaric tags for relative and absolute quanti-
tation (iTRAQ
®) technology, has not been applied to
understanding the complexity of asthma.
In the present study, we aimed to analyse the global
proteome of bronchial biopsies taken from asthmatics
and compare it to the proteome of healthy controls. In
addition, the effects of budesonide treatment on the
asthmatic bronchial proteome were also examined. Uti-
lising sensitive, high throughput iTRAQ
® technology to
quantify proteins, the resulting proteome was analysed
using Ingenuity Pathways Analysis (IPA). Distinct pro-
teome differences were observed in asthmatics
compared to controls, with increased acute phase
response and actin based signalling. The effects of glu-
cocorticoid treatment were seen with changes in the
functions displayed between placebo treated and bude-
sonide treated patients, specifically, the reduction of the
acute phase association and increased cellular processes.
This study is the first to present quantitative proteomics
of small clinically relevant tissue from asthmatic indivi-
duals, as well as determining the effects of inhaled glu-
cocorticoid treatment on this proteome.
Methods
Objectives
1. Determine if quantitative proteomic analysis of indivi-
dual biopsies can identify biologically relevant mechan-
isms of disease.
2. Determine if the proteome of bronchial biopsies are
modified with inhaled glucocorticoid treatment.
Participant Selection and Demographics
The proteomics study was conducted on 12 non-smok-
ing out-patients, aged 40-80 years, with a clinical history
of asthma. Patients had stable, mild to moderate asthma,
in accordance with the Global Initiative for Asthma
guidelines [19]. Three non-smoking, non-asthmatic sub-
jects were used as controls. Subjects were recruited and
diagnosed by a pulmonologist based on clinical history,
lung function measurements and methacholine provoca-
tion prior to inclusion in the study.
To be included in the study, subjects were required to
have abstained from inhaled and oral glucocorticoids six
weeks prior to the study and long acting bronchodilators
four weeks prior. Pregnancy was a criterion for exclu-
sion. Control subjects were required to have a baseline
FEV1 > 80% of predicted. Subjects without hypoxemia
were included.
No subject had exacerbations or respiratory infections
in the four weeks prior to their first visit or any respira-
tory disorders other than asthma. Subjects who had ser-
ious uncontrolled diseases, had any evidence of an
interfering condition by X-ray or had participated in
another clinical study in the two months prior, were
excluded from participating in the current study. Sub-
jects receiving treatment with cromolyn sodium or
nedocromyl, oral beta2 - agonists, long acting anti-choli-
nergic or leukotriene modifiers were also excluded.
Ethics Statement
The study was approved by the Regional Bioethics Com-
mittee of Kaunas University of Medicine (protocol no.
48/2004) with written informed consent received from
all participants. The study is registered with Clinical-
Trials.gov (Identifier: NCT01378039).
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The study was performed in a double blind, placebo
controlled design. The patients with asthma were rando-
mised to three months treatment with either inhaled
budesonide (400 μg twice daily) or placebo twice daily.
Salbutamol was allowed as needed.
Spirometry was performed and methacholine respon-
siveness measured using a CustovitM pneumotacho-
metric spirometer (Custo Med, Germany). Fractional
exhaled nitric oxide (FENO) was measured using the
Niox Mino
® analyzer (Aerocrine AB, Sweden) at a flow
rate of 50 mL/s. An average of three measurements was
used for analysis.
Skin prick tests (SPT) were performed using standard
allergens, Dermatophagoides pteronyssinus, Dermatopha-
goides farinae, cat epithelia, mixed mould, mixed
grasses, Betulaceae and mixed weeds (Stallergenes,
France).
Bronchial Biopsy
A bronchoscope (Olympus BF-B3R) and forceps (Olym-
pus FB-20C -1, 2.6 channel diameter, length 1050 mm;
both from Olympus Corporation, Tokyo, Japan) were
used to take endobronchial biopsies (1-2 mm) from the
left upper, middle and lower lobes, segmental and sub-
segmental bronchus. Biopsies were immediately trans-
ferred to individual microtubes and snap frozen with
liquid nitrogen, before being stored at -80°C. Control
subjects (healthy non-smokers) had bronchial biopsies
taken on one occasion only. When consenting, patients
had biopsies taken prior to, and following, the treatment
period.
Summary of Proteomics Workflow
An overview of the workflow is presented in Figure 1.
Briefly, protein extracted from bronchial biopsies was
digested into peptides, which were labelled with
iTRAQ
® Reagents. A group of four labelled samples;
three individual samples and one reference pool, were
mixed to form a four-plex set. The complexity of each
four-plex set was reduced by fractionation using strong
cation exchange chromatography (SCX). Each fraction
was then subjected to nano LC-MS/MS. The resulting
spectra were searched in a database for protein identities
and the reporter ions from the iTRAQ
® Reagents were
used to quantify proteins.
Protein Extraction
One to two middle lobe biopsies from each subject were
pooled and used for the proteomic study. Pooling of
samples into larger disease groups was not performed in
order to retain individual proteome information. Preli-
minary proteomics determined that the amount of pro-
tein extracted from individual biopsies was suitable for
iTRAQ
® analysis. Blinded endobronchial biopsies were
washed by adding 100 μl chilled milliQ water and vor-
texing. The biopsies were spun and the water discarded.
Fifty microlitres of lysis buffer (8 M urea, 4% CHAPS,
0.1% SDS, 10 mM EDTA, 5 mM TCEP) was added to
the biopsies before being sonicated in a water bath for 2
× 20 secs with a 20 sec rest between bursts. A pellet
pestle (Sigma-Aldrich Sweden AB, Sweden) was used to
Figure 1 Schematic overview of the experimental workflow.
The workflow used in the proteomics analysis of human
endobronchial biopsies. Proteins were extracted and digested,
before the peptides were labelled with iTRAQ
® Reagents in a four-
plex set. Each four-plex, containing one reference pool and three
samples, were fractionated using ion exchange chromatography.
Each fraction was then subjected to nano LC-MS/MS. The resulting
spectra were searched for identification and quantification. The
identified and quantified proteins were then analysed using
Ingenuity Pathways Analysis.
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to rinse the pestle. The homogenate was incubated for 1
hr at room temperature with shaking, followed by cen-
trifugation at 16 000 × g for 10 min. The tube was then
stored at -20°C prior to tryptic digestion. The tube was
centrifuged briefly prior to extraction of the supernatant
for further applications. The protein concentration of
each sample was determined using the Pierce BCA Pro-
tein Assay (Thermo Fisher Scientific, IL, USA). A refer-
ence pool was made by pooling aliquots from remaining
extracted protein samples. This common sample allows
for the normalisation and comparison of all sets.
iTRAQ Labelling of Peptides
65 μg of protein from each sample was withdrawn and
diluted four times with dissolution solution (0.5 M
TEAB (triethylammonium bicarbonate) and milli-Q
water)) and the samples were reduced with TCEP ((tris
(2-carboxyethyl)phosphine) and alkylated with MMTS
(methyl methanethiolsulfonate) before digestion with
trypsin (Promega Corporation, WI, USA). Each sample
in the four-plex set, consisting of one pooled reference
sample and three individual patient samples, was then
labelled with the iTRAQ
® Reagents 114, 115, 116, and
117 respectively, following manufacturer’s instructions
(Applied Biosystems, Foster City, CA, USA). The refer-
ence pool was always labelled with iTRAQ
® Reagent
114, while the patient samples were randomised to the
remaining three iTRAQ
® Reagents within the
experiment.
Strong Cation Exchange (SCX) Fractionation of iTRAQ-
labelled Peptides
SCX chromatography was used to remove unbound
iTRAQ
® Reagents and to reduce the sample complexity
by fractionation. The concentrated peptides were acidi-
fied by 10% formic acid and diluted with SCX solvent A
(25 mM ammonium formate, pH 2.8, 20% ACN (aceto-
nitrile)) and injected onto a PolySULFOETHYL A SCX
column (PolyLC Incorporated, MD, USA) (2.1 mm i.d.
×1 0c ml e n g t h ,5μm particle size, 300 Å pore size).
SCX chromatography and fractionation was carried out
on an ÄKTA purifier system (GE Healthcare, Buckin-
ghamshire, UK) at 0.25 mL/min flow rate using the fol-
lowing gradient: 0% B (500 mM ammonium formate,
pH 2.8, 20% ACN) for 5 min; 0-40% B for 20 min; 40-
100% B for 10 min and 100% B held for 10 min. UV
absorbance at 254 and 280 nm was monitored, while
fractions were collected at 0.5 mL intervals and dried
down in a SpeedVac. The 15 peptide-containing frac-
tions were desalted on PepClean C-18 Spin Columns
according to manufacturer’s instructions (Thermo Fisher
Scientific Inc, IL, USA).
LC-MS/MS Analysis on LTQ-Orbitrap
The desalted and dried fractions were reconstituted into
0.1% formic acid and analysed on an LTQ-Orbitrap XL
(Thermo Fisher Scientific) interfaced with an in-house
constructed nano-LC system, described elsewhere [20].
Briefly, 2 μl sample injections were made with an HTC-
PAL autosampler (CTC Analytics AG, Zwingen, Swit-
zerland) connected to an Agilent 1200 binary pump
(Agilent Technologies, CA, USA). The peptides were
trapped on a pre-column (45 × 0.075 mm i.d.) and sepa-
rated on a reversed phase column, 200 × 0.050 mm.
Both columns are packed in-house with 3 μmR e p r o s i l -
Pur C18-AQ particles. The flow through the analytical
column was reduced by a split to approximately 100 nl/
min and the gradient was as followed; 0-5 min 0.1% for-
mic acid, 6-103 min 7-40% ACN, 0.1% formic acid, 104-
108 min 40-80% ACN 0.1% formic acid.
LTQ-Orbitrap settings were: spray voltage 1.4 kV, 1
microscan for MS1 scans at 60 000 resolution (m/z
400), full MS mass range m/z 400-2000. The LTQ-Orbi-
trap was operated in a data-dependent mode, that is,
one MS1 scan precursor ions followed by CID (collision
induced dissociation) and HCD (high energy collision
dissociation) MS2 scans of the three most abundant
doubly or triply protonated ions in each MS1 scan. The
settings for the MS2 were as follows; 1 microscan for
H C D - M S 2a t7 5 0 0r e s o l u t i o n( a tm / z4 0 0 ) ,m a s sr a n g e
m/z 100-2000 with a collision energy of 50%, 1 micro-
scan for CID-MS2 with a collision energy of 30%.
Database Search and iTRAQ Quantification
MS raw data files from all 15 SCX fractions for one
four-plex iTRAQ set were merged for relative quantifi-
cation and identification using Proteome Discoverer ver-
sion 1.2 (Thermo Fisher Scientific). The database search
for each set was performed by the Mascot search engine
using the following criteria: Homo sapiens in Swissprot
version 2010_12, MS peptide tolerance as 5 ppm, MS/
MS tolerance as 0.5 Da, trypsin digestion allowing two
missed cleavages with variable modifications; methionine
oxidation, cysteine methylthiolation, tyrosine iTRAQ4-
plex (+144 Da) and fixed modifications; N-terminal
iTRAQ4plex, lysine iTRAQ4plex. The detected protein
threshold in the software was set to 99% confidence and
one peptide. The identified proteins were grouped by
sharing the same sequences to minimise redundancy.
For iTRAQ quantification, the ratios of iTRAQ repor-
ter ion intensities in MS/MS spectra (m/z 114.11-
117.11) from raw data sets were used to calculate fold
changes between samples. Ratios were derived by Pro-
teome Discoverer version 1.2 using the following cri-
teria: fragment ion tolerance as 50 ppm for the most
confident centroid peak, iTRAQ reagent purity
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1000 and missing values were replaced with the mini-
mum intensity. Only peptides unique for a given protein
were considered for relative quantitation, excluding
those common to other isoforms or proteins of the
same family. Proteome Discoverer normalised the chan-
nel ratios and these normalised ratios were then
exported into Excel for manual data interpretation.
Bioinformatics Analysis of Proteomic Data
Identified proteins were further analysed using IPA (ver-
sion 8.8) (Ingenuity
® Systems, http://www.ingenuity.
com) to statistically determine the functions and path-
ways most strongly associated with the protein list. Prior
to upload and analysis using IPA, the mean ratio of each
quantified protein in a group was calculated and the fold
change between the groups calculated. IPA utilises the
Ingenuity Pathways Analysis Knowledge Base (IPA KB),
a manually curated database of protein interactions
from the literature, to analyse data. A dataset containing
gene (or chemical) identifiers and corresponding expres-
sion values was uploaded into the application. Each
identifier was mapped to its corresponding object in the
IPA KB. A fold change cut-off of 1.5 was set to identify
molecules whose expression was significantly differen-
tially regulated. These proteins and their association
with the IPA KB were used to generate networks and
perform functional and canonical pathway analyses. The
significance of the associations was assessed with the
Fisher’s exact test and the Benjamini-Hochberg multiple
testing correction.
The PANTHER (Protein ANalysis THrough Evolu-
tionary Relationships) Classification System [21] was
used to further examine the significantly expressed
molecules [22].
Statistical Analysis
Differences and changes in clinical measurements were
determined using Student’s t-tests. Unpaired analyses
were used for comparing naive asthmatics to controls,
while paired t-tests were used for comparing pre and
post treatment results. The changes due to treatment
(delta change) between the two patient groups were
compared using an unpaired t-test. Data are expressed
as mean ± standard error of the mean (SEM) or as the
mean followed by range. A p value of < 0.05 was consid-
ered statistically significant.
Student’s t-tests were also used to determine signifi-
cantly modified protein expression between groups. An
unpaired t-test was performed on those proteins that
had values for at least three samples of both healthy
controls and untreated asthma. A paired t-test was
performed on those proteins that had values for at
least three samples of both pre and post treated
groups. A p value of < 0.05 was considered statistically
significant.
Principal Component Analysis
A principal component analysis (PCA) was performed
using the MultiExperiment Viewer (version 4.7), which is
part of the TM4 Microarray Software Suite [23,24]. Using
all proteins quantified in the dataset, the PCA was per-
formed to visualise the relationship between the samples.
Results
1. Clinical Characteristics of the Study Population
The age and body mass index (BMI) of the study partici-
pants did not differ significantly between three healthy
controls and the twelve untreated asthmatic patients
(Table 1). Significantly reduced lung function was observed
in asthmatics compared to controls in FEV1% predicted (p
= 0.040) (Figure 2A) and FVC% predicted (p = 0.035)
(Table 1). A significantly higher FENO was observed in
asthmatics compared to healthy controls (p = 0.04) (Figure
2B). The significant differences in FEV1% predicted and
FENO between asthmatics and controls confirmed the cor-
rect diagnosis of the individuals in this study.
2. Clinical Effects of Treatment with Budesonide
In those asthmatics patients who underwent treatment
with placebo or budesonide, and who consented to both
pre and post biopsies, the age, disease duration and BMI
were not significantly different between the two groups
Table 1 Clinical characteristics of healthy subjects and
asthmatics
Variables Healthy
subjects
Asthmatics p value
Subjects
(male/female)
3 (0/3) 12 (2/10)
Age (years)
§ 55 (42-67) 57 (38-67) 0.825
Disease duration
(years)
§
0 8 (0.5-20) na
Body Mass Index
§ 30.9 (24.1-34.9) 31.5 (19.4-41.4) 0.897
FVC (% pred.)
# 118 ± 8 86 ± 6 0.035
FEV1/FVC
# 0.85 ± 0.01 0.81 ± 0.03 0.61
PD20 (mg of
methacholine)
#
neg. or not
performed
0.13 ± 0.05
□ na
Documented SPT
positivity
08
¤
The baseline clinical characteristics of all subjects showed a statistically
significant difference in FVC % predicted between the two groups, using a
Student’s t-test. No differences were seen in the other variables. A p value of
< 0.05 was considered statistically significant (shown in bold).
Abbreviations: FEV1 = forced expiratory volume in 1 sec; FVC = forced vital
capacity; PD20 = provocative dose of methacholine producing a 20% decrease in
FEV1; FENO = fractional exhaled nitric oxide; SPT = skin prick test; na = not
applicable;
§ = data presented as mean (range);
# = data presented as mean ±
standard error of the mean;
□ = n = 10 (1 patient was negative, 1 patient was
not tested)
¤ = 2 patients were negative, 2 patients were not tested, but had no
clinical history of allergy.
O’Neil et al. Respiratory Research 2011, 12:124
http://respiratory-research.com/content/12/1/124
Page 5 of 15(Table 2). The four asthmatic patients treated with pla-
cebo showed no significant changes in lung function
parameters, FENO or methacholine reactivity, between
their pre and post treatment visits (Table 2). Treatment
with budesonide in three patients, resulted in a signifi-
cant increase in FEV1% predicted (p = 0.017), with other
parameters showing no significant changes between their
pre and post treatment visits (Table 2). The change in
clinical measurements between the pre and post treat-
ment visits (delta change) of placebo and budesonide
treated patients was not significantly different (Table 2).
3. Differences in the Bronchial Proteome of Asthmatics
Compared to Healthy Subjects
3.1 Protein Identification
A union of the three healthy controls and twelve
untreated asthmatic samples identified and quantified
1734 unique proteins relative to the reference pool (99%
confidence, one peptide, false discovery rate at p < 0.01;
1.14-7.04%). Of these, 3% were identified in all 15 sam-
ples. Of the 1734 proteins, 603 proteins were common
to both asthmatics and healthy, while 65 proteins were
unique to healthy subjects and 1066 were unique to
asthmatics.
3.2 Significantly Modified Proteins
To determine differentially expressed proteins between
healthy controls and untreated asthmatics, t-tests were
performed on valid proteins. Of the 169 proteins that
were possible to analyse statistically, seven were identi-
fied as significantly different (Table 3).
These seven proteins were mapped in IPA and dis-
played a range of protein classes and functions, includ-
ing cellular movement and immune cell trafficking.
Specifically, the IPA KB detailed roles including collagen
fibrillogenesis (dermatopontin (DPT; Q07507)), protein
elongation (ribosomal protein L7, -L8, (RPL7; P18124,
RPL8; P62917)) and chemotaxis (peptidylprolyl isomer-
ase A (cyclophilin A)(PPIA; P62937)). Three of the
molecules have been previously described in relation to
asthma, fibrosis and inflammation, including annexin 5A
(ANXA5; P08758) [25], lamin A/C (LMNA;P02545)
[26,27] and PPIA [28], indicating the sensitivity of the
method and clinical relevance of the samples.
3.3 Analysis of Functions, Pathways and Networks in
Asthmatics
To examine the protein functions and pathways of the
entire proteome, the protein ratio of asthmatics com-
pared to healthy subjects, was analysed using IPA. The
highest scoring network of proteins included the
Figure 2 FENO and FEV1% predicted of healthy controls and
asthmatics. The scatter plots show the airway inflammation and lung
function of healthy controls (n = 3) and untreated asthmatics (n =1 2 )a s
assessed by FEV1% predicted (A) and fractional exhaled nitric oxide
(FENO) (B). Asthmatics had significantly increased airway inflammation
and significantly decreased lung function, compared to healthy controls.
The bars indicate the mean ± SEM. * = indicates p value < 0.05.
Table 2 Clinical baseline and treatment effects of asthmatics receiving placebo or budesonide
Placebo Budesonide p value
Subjects (male/female) 4 (1/3) 3 (0/3)
Age (years)
§ 52 (38-64) 65 (62-67) 0.091
Disease duration (years)
§ 9 (0.5-20) 9 (5-17) 0.951
Body Mass Index
§ 29.4 (21.8-34.7) 32.0 (28.9-37.0) 0.578
Documented SPT positivity 3
¤ 2
¤¤
Pre Post p value Pre Post p value Δ p value
FEV1 (% pred.)
# 66 ± 12.52 75 ± 8.67 0.662 88 ± 14.42 101 ± 15.72 0.017 0.838
FVC (% pred.)
# 78 ± 13.46 84 ± 8.95 0.738 87 ± 13.78 101 ± 15.01 0.143 0.735
FEV1/FVC
# 0.71 ± 0.06 0.76 ± 0.07 0.472 0.85 ± 0.09 0.83 ± 0.05 0.676 0.424
PD20 (mg of methacholine)
# 0.077 ± 0.06* 0.084 ± 0.06 0.382 0.243 ± 0.14 -
† na na
FENO
# 53 ± 14.85 40 ± 9.76 0.087 46 ± 5.84 32 ± 9.14 0.092 0.880
The demographics of the asthmatics receiving placebo treatment (n = 4) and budesonide treatment (n = 3) showed no significant differences in age, disease
duration or body mass index, as determined by a Student’s t-test. The clinical measurements, pre and post treatment, were compared using a paired t-test and
showed no changes as a result of placebo treatment. Budesonide treatment resulted in a statistically increased FEV1% predicted. No significant differences were
seen for the other variables measured. A p value of < 0.05 was considered statistically significant (shown in bold).
Abbreviations: FEV1 = forced expiratory volume in 1 sec; FVC = forced vital capacity; PD20 = provocative dose of methacholine producing a 20% decrease in FEV1;
FENO = fractional exhaled nitric oxide; SPT = skin prick test;
§ = data presented as mean (range);
¤ = 1 patient was SPT negative;
¤¤ = SPT was not performed on 1
patient, but they had no clinical history of allergy;
# = data presented as mean ± standard error of the mean; na = not applicable;* = PD20 measurements were only
available for three patients; † = PD20 measurement was only available for one patient; Δ = delta change.
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function”, “lipid metabolism” and “molecular transport”.
This network included haemoglobins, apolipoproteins 1
and MHC class I (Figure 3). The network also included
RPL8, a protein involved in protein synthesis, which was
identified as significantly different between healthy con-
trols and asthmatics. In addition, IPA analysis of the dif-
ferentially expressed proteins of untreated asthmatics
identified associations with the biological functions of
“respiratory disease”, “cell to cell signalling”, “haematolo-
gical system development and function” and “tissue
development” (data not shown). The top canonical path-
ways associated with proteins from asthmatics included
“acute phase response signalling” and “intrinsic pro-
thrombin activation pathway”, while the toxicology lists
include “positive acute phase response proteins”“ oxida-
tive stress” and “negative acute phase response proteins”
(data not shown). The association between the mole-
cules differentially expressed in the asthmatics and the
functions, networks and pathways above suggest
increased haematological involvement and increased oxi-
dative stress in asthmatics compared to controls.
4. The Effect of Placebo vs Budesonide on the Bronchial
Proteome of Asthmatics
4.1 Protein Identification
In the biopsies from placebo treated asthmatics, 1333
proteins were quantified in at least one of the four pre
placebo biopsies, with 9.2% being quantified in all four.
In the post placebo biopsy proteomes, 683 proteins were
quantified, with 9.8% being quantified in all four sam-
ples. Of the 1446 unique proteins identified in at least
one of these samples, 570 were common to both the pre
and post placebo proteome, while 763 proteins were
unique to the pre placebo samples and 113 proteins
unique to the post placebo samples. Examining the
paired biopsies, 58 proteins were quantified in both pre
and post placebo biopsies of all four asthmatics.
In biopsies from budesonide treated asthmatics, 1234
proteins were quantified in at least one of the three pre
budesonide biopsies, with 14.7% of proteins quantified
in all three biopsy proteomes. In post budesonide sam-
ples, a total of 854 proteins were quantified in at least
one of three post budesonide biopsies, with 29.9% of
proteins quantified in all three individuals. Of the 1419
unique proteins identified in at least one of these sam-
ples, 669 proteins were common to both the pre and
post budesonide proteome, while 565 proteins were
unique to the pre budesonide samples and 185 proteins
were unique to the post budesonide samples. Comparing
the paired pre and post budesonide biopsies, 141 pro-
teins were quantified in both biopsies of all three
subjects.
In all placebo and budesonide treated individuals, 54
proteins were quantified in all asthmatics, in both their
pre and post treatment biopsies.
4.2 Significantly Modified Proteins
Of the 115 proteins that could be statistically analysed
for placebo treated patients, three were identified as sig-
nificantly different between pre and post placebo biop-
sies (Table 4), while seven of 141 proteins were
identified as significantly modified between pre and post
budesonide biopsies (Table 5). The proteins that chan-
ged significantly during placebo treatment were different
from those significantly modified with budesonide
treatment.
The significantly changed proteins in the placebo trea-
ted group reflect the natural progression of disease
(Table 4). The proteins have a variety of functions,
annotated by the IPA KB, including cell movement
(actin, beta (ACTB; P60709), the disruption of microtu-
bules (keratin 18 (KRT18; P05783)) and production of
reactive oxygen species (serpin peptidase inhibitor, clade
A, member 1 (SERPINA1; P01009)). The increased
expression of SERPINA1 suggests an increase in inflam-
matory processes in placebo treated patients, while the
Table 3 The significantly differentially expressed proteins in untreated asthmatics compared to healthy controls
Swiss Prot Acc. No. Symbol Entrez Gene Name Fold Change Location Protein Class
P08758 ANXA5 annexin A5 -1.98 Plasma membrane transfer/carrier protein
Q07507 DPT dermatopontin -2.15 Extracellular space extracellular matrix binding protein
Q96KK5 HIST1H2AH histone cluster 1, H2ah -2.85 Nucleus histone
P02545 LMNA lamin A/C -1.85 Nucleus structural protein
P62937 PPIA peptidylprolyl isomerase A (cyclophilin A) -1.64 Cytoplasm isomerase
P18124 RPL7 ribosomal protein L7 -1.82 Cytoplasm ribosomal protein
P62917 RPL8 ribosomal protein L8 -1.76 Cytoplasm ribosomal protein
© 2000-2011 Ingenuity Systems, Inc. All rights reserved.
All listed proteins showed a statistically significant difference (p value < 0.05) between the groups using a Student’s t-test. The fold change for each protein is
calculated by dividing the average ratio of the untreated asthmatics with the average ratio of the healthy controls. The negative fold change indicates down
regulation of protein expression in asthmatic patients. The cell location of the protein is annotated by IPA. The protein class is determined using the PANTHER
Classification System.
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Page 7 of 15Figure 3 Network of differentially expressed proteins in untreated asthmatics compared to healthy controls. The top network generated
by Ingenuity Pathways Analysis from quantified proteins (1.5 fold change threshold) of untreated asthmatics compared to healthy controls,
contains the functions of haematological system development and function, lipid metabolism and molecular transport. Molecules with bold
outline are significantly different between the two groups using a Student’s t-test. Lines indicate relationships between molecules. Arrows at the
end of these lines indicated the direction of the interaction. Molecules that are up-regulated and down-regulated in the dataset are coloured
red and green respectively. Grey molecules do not meet the cut-off threshold. Uncoloured molecules have been added from the Ingenuity
Knowledge Base. Entrez gene names for molecules are: ACAT1 = acetyl-CoA acetyltransferase 1, APOA1 = apolipoprotein A-I, APOA2 = apolipoprotein
A-II, CA2 = carbonic anhydrase II, CAP1 = CAP, adenylate cyclase-associated protein 1 (yeast), CS = citrate synthase, GLO1 = glyoxalase I, GOLGA3 =
golgin A3, HBB = hemoglobin (beta), HBD = hemoglobin (delta), HBG1 = hemoglobin (gamma A), HLA-B = major histocompatibility complex, class I,
B, HNRNPH1 = heterogeneous nuclear ribonucleoprotein H1 (H), MVP = major vault protein, MYLK = myosin light chain kinase, NONO = non-POU
domain containing, octamer-binding, PAK2 = p21 protein (Cdc42/Rac)-activated kinase 2, RAB14 = RAB14, member RAS oncogene family, RPL8 =
ribosomal protein L8, SYNCRIP = synaptotagmin binding, cytoplasmic RNA interacting protein, TAGLN2 = transgelin 2, TARDBP = TAR DNA binding
protein, TNS1 = tensin 1, TPM3 = tropomyosin 3, UQCRB = ubiquinol-cytochrome c reductase binding protein, UQCRC2 = ubiquinol-cytochrome c
reductase core protein II, VASP = vasodilator-stimulated phosphoprotein.
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Page 8 of 15decreased expression of ACTB suggests dysregulated
growth and proliferation.
The significantly modified proteins in the budesonide
treated proteome may reflect the proteomic changes
induced by the glucocorticoid (Table 5). Of the seven
proteins, several were involved in inflammatory and
immunological disorders; alpha-2-macroglobulin (A2M;
P01023), aldolase A (ALDOA; P04075), serpin peptidase
inhibitor, clade B, member 3 (SERPINB3; P29508),
vimentin (VIM; P08670)), as well as cell movement
(SERPINB3) and energy production (ATP synthase, H+
transporting, mitochondrial F1 complex, beta polypep-
tide (ATP5B; P06576). Of interest, a cytokine, A2M, was
identified and quantified. The quantification of several
cytokines identified in this study, including secretoglo-
bin, family 1A, member 1 (SCGB1A1; P11684) and
tumour necrosis factor (ligand) superfamily, member
13b (TNFSF13B; Q9Y275), indicates the sensitivity of
the proteomics method used. The decreased expression
of A2M and VIM suggests possible suppression of
inflammation in response to budesonide.
4.3 Analysis of the Effect of Treatment on Functions and
Pathways
The quantified proteins of the paired biopsies treated
with either placebo or budesonide were analysed using
IPA. The analysis of the post placebo proteins changed
more than 1.5 fold compared to the pre placebo control
biopsy, revealed that the top network contained the
functions “hair and skin development and function”,
“organ development” and “dermatological diseases and
conditions” (Figure 4). The network displays three dis-
tinct nodes; the NF-kB complex, the IgG complex and
the cytokeratin complex.
The most relevant biological functions following placebo
treatment included “gastrointestinal disease”, “cell-to-cell
signalling and interaction” and “tissue development”, while
top canonical pathways showed an association with actin-
based signalling pathways, suggesting increased structural
modification events. This was then followed by the acute
phase response and prothrombin activation pathways.
Budesonide is a common anti-inflammatory glucocor-
ticoid used to treat asthma. “Cell movement”, “cell
growth and proliferation”, and “cell to cell signalling and
interaction” were the top biological functions associated
with post budesonide asthma, compared to pre budeso-
nide. The top network of post budesonide proteins
included the functions “cancer”, “genetic disorder” and
“respiratory disease” (Figure 5). This network includes
two proteins which were determined to be significantly
modified in response to treatment. VIM is a cytoskeletal
Table 4 Significantly modified proteins in post treated placebo versus pre treated placebo asthmatic patients
Swiss Prot Acc. No. Symbol Entrez Gene Name Fold Change Location Protein Class
P60709 ACTB actin, beta -1.66 Cytoplasm actin and actin related protein
P05783 KRT18 keratin 18 1.31 Cytoplasm structural protein
P01009 SERPINA1 serpin peptidase inhibitor, clade A
(alpha-1 antiproteinase, antitrypsin), member 1
2.34 Extracellular space serine protease inhibitor
© 2000-2011 Ingenuity Systems, Inc. All rights reserved.
All listed proteins showed a statistically significant difference (p value < 0.05) between the groups using a Student’s t-test. The fold change for each protein is
calculated by dividing the average ratio of the placebo post treated biopsy with the average ratio of the paired pre placebo biopsy. The negative fold change
indicates down regulation of protein expression by placebo, while the positive fold change indicates up regulation by placebo. The cell location of the protein is
annotated by IPA. The protein class is determined using the PANTHER Classification System.
Table 5 Significantly modified proteins in post treated budesonide versus pre treated budesonide asthmatics
Swiss Prot Acc. No. Symbol Entrez Gene Name Fold Change Location Protein Class
P01023 A2M alpha-2-macroglobulin -1.27 Extracellular space cytokine
P04075 ALDOA aldolase A, fructose-bisphosphate -1.22 Cytoplasm aldolase
P06576 ATP5B ATP synthase, H+ transporting,
mitochondrial F1 complex, beta polypeptide
-1.76 Cytoplasm ATP synthase
Q9BPU6 DPYSL5 dihydropyrimidinase-like 5 2.01 Cytoplasm hydrolase
P60866 RPS20 ribosomal protein S20 1.54 Cytoplasm ribosomal protein
P29508 SERPINB3 serpin peptidase inhibitor,
clade B (ovalbumin), member 3
2.31 Extracellular space serine protease inhibitor
P08670 VIM vimentin -1.69 Cytoplasm structural protein
© 2000-2011 Ingenuity Systems, Inc. All rights reserved.
All listed proteins showed a statistically significant difference (p value < 0.05) between the groups using a Student’s t-test. The fold change for each protein is
calculated by dividing the average ratio of the budesonide post treated biopsy with the average ratio of the paired pre budesonide biopsy. The negative fold
change indicates down regulation of protein expression after budesonide treatment, while the positive fold change indicates up regulation after budesonide
treatment. The cell location of the protein is annotated by IPA. The protein class is determined using the PANTHER Classification System.
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Page 9 of 15protein, while dihydropyrimidinase-like 5 (DPYSL5;
Q9BPU6) plays a role in growth and guidance.
The most relevant canonical pathways following budeso-
nide treatment included prothrombin activation pathways
followed by actin motility and signalling, suggesting an
involvement in vascular exudation and remodelling. This
is further confirmed by the top toxicology list association
of hepatic fibrosis (data not shown). Specifically, the
Figure 4 Network of differentially expressed proteins of post placebo compared to paired pre placebo biopsy.T h et o pn e t w o r k
generated by Ingenuity Pathways Analysis from quantified proteins of post placebo asthmatics compared to their pre placebo biopsy. The
network contains the functions of hair and skin development and function, organ development, dermatological diseases and conditions.
Molecules with bold outline are significantly different between the two groups using a Student’s t-test. Lines indicate relationships between
molecules. Arrows at the end of these lines indicated the direction of the interaction. Molecules that are up-regulated and down-regulated in
the dataset are coloured red and green respectively. Grey molecules do not meet the cut-off threshold. Uncoloured molecules have been added
from the IPA KB. Entrez gene names for molecules are: CFL1 = cofilin 1 (non-muscle) DES = desmin, E2F7 = E2F transcription factor 7, HDGF =
hepatoma-derived growth factor, HRG = histidine-rich glycoprotein, IGHG3 = immunoglobulin heavy constant gamma 3 (G3 m marker), IGHG4 =
immunoglobulin heavy constant gamma 4 (G4 m marker), IGKC = immunoglobulin kappa constant, KRT2 = keratin 2, KRT4 = keratin 4, KRT5 =
keratin 5, KRT8 = keratin 8, KRT9 = keratin 9, KRT13 = keratin 13, KRT14 = keratin 14, KRT15 = keratin 15, KRT17 = keratin 17, KRT19 = keratin 19,
KRT6A = keratin 6A, PPIF = peptidylprolyl isomerase F, PPL = periplakin, S100P = S100 calcium binding protein P, SERPINA4 = serpin peptidase
inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 4, TACSTD2 = tumor-associated calcium signal transducer 2, TMOD2 = tropomodulin 2
(neuronal), TNFSF13B = tumor necrosis factor (ligand) superfamily, member 13b, TPI1 = triosephosphate isomerase 1, TPM1 = tropomyosin 1 (alpha).
O’Neil et al. Respiratory Research 2011, 12:124
http://respiratory-research.com/content/12/1/124
Page 10 of 15decreased expression of some collagen proteins suggests
that the remodelling process is being suppressed.
Comparing the placebo and budesonide analyses, pla-
cebo treatment was generally associated with tissue
development and actin based signalling, which was dif-
ferent to the budesonide treated with more associations
to cellular functions and prothrombin activation (data
not shown). Importantly, the placebo treatment was
Figure 5 Network of differentially expressed proteins of post budesonide compared to paired pre treatment biopsy. The top network
generated by Ingenuity Pathways Analysis from quantified proteins of post budesonide asthmatics compared to their pre placebo biopsy. The
network contains the functions of cancer, genetic disorder and respiratory disease. Molecules with bold outline are significantly different
between the two groups using a Student’s t-test. Lines indicate relationships between molecules. Arrows at the end of these lines indicated the
direction of the interaction. Molecules that are up-regulated and down-regulated in the dataset are coloured red and green respectively. Grey
molecules do not meet the cut-off threshold. Uncoloured molecules have been added from the IPA KB. Entrez gene names for molecules are:
CAPNS1 = calpain, small subunit 1, CAST = calpastatin, CFL1 = cofilin 1 (non-muscle), CKB = creatine kinase, brain, DPYSL2 = dihydropyrimidinase-like
2, DPYSL3 = dihydropyrimidinase-like 3, DPYSL5 = dihydropyrimidinase-like 5, DYNLL2 = dynein, light chain, LC8-type 2, ENO1 = enolase 1, (alpha), GPI
= glucose-6-phosphate isomerase, H2AFX = H2A histone family, member X, HNRNPD = heterogeneous nuclear ribonucleoprotein D (AU-rich element
RNA binding protein 1, 37 kDa), HYOU1 = hypoxia up-regulated 1, ILF3 = interleukin enhancer binding factor 3, 90 kDa, KRT4 = keratin 4, KRT9 =
keratin 9, KRT6A = keratin 6A, LDHA = lactate dehydrogenase A, PPP1CC = protein phosphatase 1, catalytic subunit, gamma isozyme, RPL31 =
ribosomal protein L31, SERBP1 = SERPINE1 mRNA binding protein 1, SYNCRIP = synaptotagmin binding, cytoplasmic RNA interacting protein, TTR =
transthyretin, VIM = vimentin, XRCC5 = X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining), YWHAE
= tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptide, YWHAZ = tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta polypeptide.
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Page 11 of 15associated with hepatic fibrosis and positive acute phase
proteins. These associations were reduced in budesonide
treatment, with a drastically decreased association with
acute phase proteins.
A PCA was performed in order to visualise the rela-
tionship between the 22 samples, including healthy con-
trols, untreated asthmatics, placebo treated asthmatics
and budesonide treated asthmatics. A total of 1833
unique proteins were identified in at least one of the 22
samples in the dataset and the expression data analysed
by PCA. Principal components 1 and 2 represented
37.47% of the overall variability of the data. A biplot of
these two components revealed a tight cluster of healthy
controls, within a larger cluster of asthmatics. The pro-
teome of two untreated asthmatics, two post placebo
asthmatics and one post budesonide asthmatic separate
from the main cluster (data not shown). The PCA sug-
gests minimal variation in the proteome of the healthy
controls and demonstrated the known heterogeneity of
asthma.
Discussion
There has been rapid growth in the identification of bio-
markers and mechanisms using proteomic methods.
Clinical proteomics is challenged by limited patient
numbers and limited patient material. This study has
shown for the first time that bronchial biopsy material
can contain sufficient material for quantitative proteo-
mic analysis. In addition, the individual proteomes of
patients can be determined and features of asthma,
including structural changes and cellular movement, can
be identified.
T h ec u r r e n ts t u d yh a ss h o w nf o rt h ef i r s tt i m et h a t
small clinically relevant tissue samples (bronchial biop-
sies) can be used to successfully analyse the proteome of
patients with asthma. By combining iTRAQ
® technology
with sensitive LC-MS/MS, proteins extracted from
endobronchial biopsies were identified and it was possi-
ble to quantify characteristics of asthma, including the
expression of proteins involved in oxidative stress,
immune cell trafficking and inflammatory responses.
Importantly, we also show that treatment with an
inhaled glucocorticoid significantly affects the proteome
and associated relevant functions, again arguing that
quantitative proteomic studies can identify disease rele-
vant processes in the bronchi and can reflect responses
to treatment.
The number of patients utilised for this proteomics
study was relatively low, as bronchial biopsies were not
available from all subjects due to some declining to
undergo bronchoscopies. As this was not anticipated, it
is unlikely that a selection bias for the bronchial biopsy
results was introduced. Despite the low numbers, a sig-
nificant difference in several measurements was found
between the studied groups and the paired samples add
strength to the study. It is interesting to observe that
both FEV1% predicted and FENO were significantly dif-
ferent in the asthma group compared with the controls,
confirming the correct diagnosis of the individuals.
Despite being far from powered, the study was able to
determine clinical effects of inhaled glucocorticoids, as
observed by an improvement in percent predicted FEV1
by the applied treatment, again confirming the correct
diagnosis and clinically relevant treatment effects. Future
screening studies of this depth will probably be con-
ducted in small patient subsets, due to the invasive nat-
ure of the sampling. The current study is not only the
first to utilise quantitative proteomics in bronchial biop-
sies in asthma, but also the largest study determining
the proteome of asthma.
The bronchial biopsies from the asthmatics, taken
through fibreoptic bronchoscopes, are a few milli-
metres in size, subsequentlyr e s u l t i n gi nas m a l ly i e l d
of extracted protein. Despite these limitations, the cou-
pling of the iTRAQ
® technology and the nanoLC-
LTQ-Orbitrap XL instrument successfully identified a
large number of proteins in the samples, including
many that were relevant to asthma and respiratory dis-
eases. As might be expected from tissue samples, the
currently applied technique was able to identify and
quantify a larger number of proteins than any previous
proteomic study in asthma using BALF [10] or specific
cells [11,29], despite no affinity depletion of high abun-
dance proteins. Interestingly, the low abundance of
cytokines usually prevents their quantification in pro-
teomics studies. However, this study has identified and
quantified several cytokines in bronchial biopsies,
including SCGB1A1 and TNFSF13B. These two cyto-
kines had increased expression with placebo treatment,
which was reduced in budesonide treatment. SCGB1A1
is a transient marker of inflammation [30], while
TNFSF13B has been associated with both Th1 and
Th2 inflammation [31,32]. Other cytokines identified,
but not quantified, included interleukin 6, chemokine
(C-C motif) ligand 5 (CCL5; P13501) and macrophage
migration inhibitory factor (MIF; P14174), again docu-
menting the relatively high sensitivity of the proteo-
mics method utilised. Currently, no proteomics
method will identify and quantify all proteins present
in a biological sample. The identification of low abun-
dant proteins such as cytokines and other regulatory
molecules, which may have profound biological effects
at low concentrations, may require an even more sen-
sitive methodology to be adequately measured. It is
possible that with exclusion lists of irrelevant proteins,
many more low abundance proteins could be identified
[33]. In addition, multiple reaction monitoring mass
spectrometry may also allow the identification of low
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validation [34].
Both the significant proteins, as well as the IPA
results, show clear differences in the proteome of bron-
chial biopsies of asthmatics vs healthy controls. Asthma
relevant proteins that were shown to be different in
asthmatics vs controls included SCGB1A1, SERPINA1,
thrombins and fibrinogens. LMNA, one of the signifi-
cantly differentially expressed proteins of asthmatics, has
been shown to be decreased in fibroblasts from fibrotic
lungs compared to non-fibrotic lungs [27]. The altered
expression of these proteins in the bronchi of asthmatics
supports the evidence of inflammatory process in the
airways of the studied individuals. Interestingly, the top
network expressed in asthma vs controls connects “hae-
matological system development and function” with
“lipid metabolism” and “molecular transport”.
After treatment with placebo, the proteomic analysis
showed some significantly modified proteins between
post and pre treatment. The expression of these proteins
may occur for two possible reasons. Firstly, they may be
due in part to inherent experimental variation, perhaps
depending on slight differences in the cellular composi-
tion in the biopsies. Secondly, the changes during pla-
cebo treatment could be due to the natural progression
of disease over the treatment period.
Treatment with budesonide changes protein expres-
sion to a larger extent than placebo treatment and sev-
eral of these changed proteins, including fibronectin
(FN1; P02751) and SCGB1A1, are likely to be related to
effects of the glucocorticoid. The top network of mole-
cules generated for budesonide treatment included “can-
cer”, “genetic disorder” and “respiratory disease” and
includes proteins such as keratin 6A (KRT6A; P02538),
dihydropyrimidinase-like 5 (DPYSL5; Q9BPU6), and
interleukin enhancer binding factor 3 (ILF3; Q12906)
which had increased expression, while downregulated
proteins included cofilin 1(CFL1; P23528), alpha enolase
1(ENO1; P06733) and VIM (Figure 5). ILF3, has recently
been described as a regulator of HS4-dependent IL13
transcription, an important cytokine in Th2 immune
responses [35]. A decreased expression of VIM, a
mesenchymal marker, may suggest reduced remodelling
in response to budesonide, as epithelial to mesenchymal
transition has been seen to contribute to remodelling
[36,37]. With roles in inflammation and remodelling,
these proteins will need to be validated and further
investigated as potential targets.
Inhaled glucocorticoids are potent anti-inflammatories
recommended for asthmatics. Budesonide has been seen
to reduce inflammatory cells [38] and correct gene
expression [39] in bronchial biopsies, however, global
proteome changes had not been analysed. A biological
function that is significantly affected by inhaled
budesonide is “immune cell trafficking”, in addition to
the functions of “tissue development” and “haematologi-
cal systems development and function”,w h i c hw a s
observed to change during placebo treatment and is also
different between untreated asthma and controls. The
general anti-inflammatory effect of budesonide can be
seen with the improved lung function of the asthmatics
and with the reduced association with acute phase pro-
teins. Thus, our data show that protein networks and
functions relevant, or likely to be relevant, to asthma,
are altered by inhaled glucocorticoids.
The application of iTRAQ
® technology with LC-MS/
MS has been used in several other diseases and samples
[14,15]. This study is the first to describe the application
of this method to examine the asthmatic bronchial
biopsy proteome and effects of glucocorticoid treatment.
Studying the proteome of asthma is a complicated task,
for several reasons. For one, the heterogeneity of asthma
argues the existence of several different subtypes of dis-
ease and the current study is too small to include sub-
classifications of disease [40]. The principal component
analysis allowed the visualisation of the relationship
between the samples of this study. While the healthy
controls clustered together, as anticipated, the asthmatic
samples showed more variability. This may reflect the
known variability of the disease, with its multiple pheno-
types [41]. The budesonide treated samples did not clus-
ter together, which is not unexpected, as the response
the inhaled glucocorticoids can vary substantially
between asthmatic patients [42]. Therefore, this study
reflects the mechanism and features of asthma in gen-
eral and will need to be expanded in phenotypes of
asthma to further dissect the mechanisms of disease.
A limitation of the current study is the experimental
and biological variation occurring at multiple levels. This
is true for any clinical proteomics study of clinical pro-
teomics in disease, but is especially relevant in asthma, a
disease with extensive variability in intrinsic biological
activity over time. It must be cautioned that to develop
relevant biomarkers of disease from the current study,
the results will need to be further validated by other
methods in order to address the limitations of potential
false discovery, small sample size and gender specific pro-
teome differences. Following this, verification will be
required in an independent group of patients, as well as
other inflammatory and respiratory diseases. While the
findings of the current study have not been validated, the
results from the IPA support their involvement in pro-
cesses associated with asthma, including structural
changes, collagen accumulation and angiogenesis [43].
Conclusions
This extensive proteomic study has identified global
mechanisms and features common to asthma and has
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Page 13 of 15determined for the first time that these features can be
identified from small biopsy samples of individuals with
the disease. However, the limited patient number and
heterogeneity of asthma argues that even more detailed
studies will be required in the future to identify new
mechanisms of disease. Thus, to further understand the
complexities of asthma in the many phenotypes that are
displayed, well characterised subsets of patients, repre-
senting different phenotypes of asthma will need to be
examined.
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